1415798-06-9

Upstream product

• 1415798-03-6 methyl 1-methyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-7-formate 
• 615568-47-3 methyl 2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-7-formate 
• 924279-03-8 methyl 6-(2-methoxy-2-carbonylethoxy)-5-nitronicotinate 
• 1415798-04-7 methyl 1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-7-formate 
• 1415798-05-8 methyl 1-methyl-6-oxo-2,3,5,6-tetrahydro-1H-pyrido[2,3-b][1,4]oxazine-7-formate 
• 1765-93-1 4-fluoroboronic acid 

Downstream Products

• 1415798-07-0 5-(4-fluorophenyl)-1-methyl-6-oxo-2,3,5,6-tetrahydro-1H-pyrido[2,3-b][1,4]oxazine-7-formic acid 
• 1415798-56-9 N-(4-(2-aminopyridine-4-oxy)-3-fluorophenyl)-5-(4-fluorophenyl)-1-methyl-6-oxo-2,3,5,6-tetrahydro-1H-pyrido[2,3-b][1,4]oxazine-7-formamide 

Relevant academic research and scientific papers

HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.